Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
The goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs was quantified from fifty-five late stage gastric cancer FFPE spec...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3158077?pdf=render |
| _version_ | 1818581626431471616 |
|---|---|
| author | Jingting Jiang Xiao Zheng Xiao Xu Qi Zhou Haijiao Yan Xueguang Zhang Binfeng Lu Changping Wu Jingfang Ju |
| author_facet | Jingting Jiang Xiao Zheng Xiao Xu Qi Zhou Haijiao Yan Xueguang Zhang Binfeng Lu Changping Wu Jingfang Ju |
| author_sort | Jingting Jiang |
| collection | DOAJ |
| description | The goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs was quantified from fifty-five late stage gastric cancer FFPE specimens.Gastric cancer patients with KPS>70 were recruited for the trial. The control group was treated with 400 mg/twice/day Doxifluridine plus i.v. with Oxaliplatin at 130 mg/m(2)/first day/4 week cycle. The testing group was treated with S-1 at 40 mg/twice/day/4 week cycle plus i.v. with Oxaliplatin at 130 mg/m(2)/first day/4 week cycle. Total RNAs were extracted from normal and gastric tumor specimens. The levels of miRNAs were quantified using real time qRT-PCR expression analysis.The overall objective response rate (CR+PR) of patients treated with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6% (CR+PR) with Doxifluridine/Oxaliplatin for advanced stage gastric cancer patients. The average overall survival for patients treated with S-1/Oxaliplatin was 7.80 month vs. 7.30 month with patients treated with Doxifluridine/Oxaliplatin. The expression of miR-181b (P = 0.022) and miR-21 (P = 0.0029) was significantly overexpressed in gastric tumors compared to normal gastric tissues. Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard ratio: 0.17, CI = 0.06-0.45; P = 0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI = 0.16-0.87; P = 0.018) are closely associated with better patient's overall survival for both S-1 and Doxifluridine based regimens.Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin. miR-21 and miR-181b hold great potential as prognostic biomarkers in late stage gastric cancer. |
| first_indexed | 2024-12-16T07:36:29Z |
| format | Article |
| id | doaj.art-7273898aa3864ec0a2852a2576163626 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T07:36:29Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7273898aa3864ec0a2852a25761636262022-12-21T22:39:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0168e2327110.1371/journal.pone.0023271Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.Jingting JiangXiao ZhengXiao XuQi ZhouHaijiao YanXueguang ZhangBinfeng LuChangping WuJingfang JuThe goal of this study is to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in gastric cancer patients. The expression of candidate miRNAs was quantified from fifty-five late stage gastric cancer FFPE specimens.Gastric cancer patients with KPS>70 were recruited for the trial. The control group was treated with 400 mg/twice/day Doxifluridine plus i.v. with Oxaliplatin at 130 mg/m(2)/first day/4 week cycle. The testing group was treated with S-1 at 40 mg/twice/day/4 week cycle plus i.v. with Oxaliplatin at 130 mg/m(2)/first day/4 week cycle. Total RNAs were extracted from normal and gastric tumor specimens. The levels of miRNAs were quantified using real time qRT-PCR expression analysis.The overall objective response rate (CR+PR) of patients treated with S-1/Oxaliplatin was 33.3% (CR+PR) vs. 17.6% (CR+PR) with Doxifluridine/Oxaliplatin for advanced stage gastric cancer patients. The average overall survival for patients treated with S-1/Oxaliplatin was 7.80 month vs. 7.30 month with patients treated with Doxifluridine/Oxaliplatin. The expression of miR-181b (P = 0.022) and miR-21 (P = 0.0029) was significantly overexpressed in gastric tumors compared to normal gastric tissues. Kaplan-Meier survival analysis revealed that low levels of miR-21 expression (Log rank test, hazard ratio: 0.17, CI = 0.06-0.45; P = 0.0004) and miR-181b (Log rank test, hazard ratio: 0.37, CI = 0.16-0.87; P = 0.018) are closely associated with better patient's overall survival for both S-1 and Doxifluridine based regimens.Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin. miR-21 and miR-181b hold great potential as prognostic biomarkers in late stage gastric cancer.http://europepmc.org/articles/PMC3158077?pdf=render |
| spellingShingle | Jingting Jiang Xiao Zheng Xiao Xu Qi Zhou Haijiao Yan Xueguang Zhang Binfeng Lu Changping Wu Jingfang Ju Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS ONE |
| title | Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. |
| title_full | Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. |
| title_fullStr | Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. |
| title_full_unstemmed | Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. |
| title_short | Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. |
| title_sort | prognostic significance of mir 181b and mir 21 in gastric cancer patients treated with s 1 oxaliplatin or doxifluridine oxaliplatin |
| url | http://europepmc.org/articles/PMC3158077?pdf=render |
| work_keys_str_mv | AT jingtingjiang prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT xiaozheng prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT xiaoxu prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT qizhou prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT haijiaoyan prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT xueguangzhang prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT binfenglu prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT changpingwu prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin AT jingfangju prognosticsignificanceofmir181bandmir21ingastriccancerpatientstreatedwiths1oxaliplatinordoxifluridineoxaliplatin |